NXL
Nexalin Technology, Inc. NASDAQ$0.38
Mkt Cap $7.8M
52w Low $0.33
3.0% of range
52w High $2.00
50d MA $0.42
200d MA $0.81
P/E (TTM)
-0.8x
EV/EBITDA
-1.0x
P/B
1.7x
Debt/Equity
0.0x
ROE
-219.4%
P/FCF
-1.8x
RSI (14)
—
ATR (14)
—
Beta
4.23
50d MA
$0.42
200d MA
$0.81
Avg Volume
608.3K
About
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.12 | -0.13 | -8.3% | 0.40 | -3.0% | -5.1% | -8.1% | -10.9% | -12.1% | -10.5% | — |
| Nov 14, 2025 | AMC | -0.12 | -0.13 | -8.3% | 1.08 | +0.0% | +0.0% | -1.9% | -2.8% | -9.1% | -6.5% | — |
| Aug 6, 2025 | AMC | -0.10 | -0.10 | +0.0% | 0.99 | -3.0% | -5.8% | -9.1% | -10.1% | -11.2% | -15.4% | — |
| May 13, 2025 | AMC | -0.10 | -0.15 | -50.0% | 1.19 | +0.0% | +2.5% | +4.2% | +6.7% | +6.7% | +3.4% | — |
| Mar 14, 2025 | AMC | -0.12 | -0.28 | -133.3% | 2.15 | +9.8% | +10.2% | +2.3% | +14.0% | +15.3% | +10.7% | — |
| Nov 8, 2024 | AMC | -0.12 | -0.23 | -91.7% | 3.80 | +0.5% | -12.1% | -0.5% | +3.2% | +7.9% | +11.1% | — |
| Aug 8, 2024 | AMC | — | -0.17 | — | 0.91 | -3.0% | +4.5% | +1.5% | +5.8% | +8.5% | +8.1% | — |
| May 10, 2024 | AMC | — | -0.14 | — | 1.28 | -1.6% | -3.1% | +7.0% | +6.2% | +3.9% | +2.3% | — |
| Mar 27, 2024 | AMC | — | -0.10 | — | 0.78 | +11.5% | +79.5% | +143.6% | +267.9% | +207.7% | +175.6% | — |
| Nov 13, 2023 | AMC | — | -0.31 | — | 0.34 | +0.0% | -15.9% | -10.9% | -15.3% | -10.6% | -10.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Maxim Group | Upgrade | Hold → Buy | — | $2.38 | $2.43 | +2.1% | -1.7% | -9.2% | -12.2% | -13.4% | -19.7% |
| Dec 5 | Maxim Group | Downgrade | Buy → Hold | — | $4.15 | $4.11 | -1.0% | +0.5% | +5.1% | +4.8% | -4.1% | +1.7% |
Recent Filings
8-K · 1.01
!! High
Nexalin Technology, Inc. -- 8-K 1.01: Material Agreement
Nexalin Technology entered a material agreement with Lindus Health Limited, though specific terms remain undisclosed in this initial filing notification.
Apr 22
8-K · 7.01
! Medium
Nexalin Technology, Inc. -- 8-K 7.01: Regulation FD Disclosure
Nexalin Technology partnered with Lindus Health to conduct a clinical study, potentially advancing its therapeutic technology toward regulatory approval and commercialization.
Feb 25
Data updated apr 26, 2026 4:33pm
· Source: massive.com